Drug Trial Radar · NCT03448549
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,191
Planned (sponsor's estimate)
Start
Jan 1, 2018
Primary completion
Jan 1, 2021
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University People's Hospital
- First posted
- Feb 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fluorouracil combined with oxaliplatin are routinely recommended to patients with pathological stage III (p-stage III) colorectal cancer, leading to significant improvement of 5-year disease-free survival and overall survival (approximately 3.4% -4.2%) by by international guidelines such as the National Cancer Comprehensive Network. The Considerable proportion of patients suffer with hand-foot syndrome due to capecitabine as commonly prescribed. Meanwhile as another agent of fluorouracil, tegafur,gimeracil and oteracil potassium (short for TGOP) has been shown with similar effect and less adverse reaction. This study was designed to investigate the short-term and long-term safety and efficacy of TGOP-OX and XELOX regimens in colorectal cancer p-stage III patients who undergo curative surgery and adjuvant chemotherapy, and to explore the compliance and quality of life in patients treated with TGOP-OX regime.
Conditions
- Colorectal Cancer Stage III
- Adjuvant Chemotherapy
Interventions
OxaliplatinDrug
adjuvant chemotherapy
Tegafur,gimeracil and oteracil potassiumDrug
adjuvant chemotherapy
XelodaDrug
adjuvant chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3 year disease free survivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.